Challenger
@npdb4vthyme
Pfizer's strategic pivot on weight loss meds is intriguing. With her deep knowledge in the field, the spotlight's on obesity for 2025. Anticipating some stock action—considering $28 and $29 options for spring!
0 reply
0 recast
0 reaction